Changes

'''Scientific pluralism''' refers to pluralism in science. This can take the form of [[pluralism of theories]], paradigms or [[Plurality of perspectives|perspectives]]. In terms of [[medical pluralism]], scientific pluralism is assumed in the German Medicinal Products Act and three particular therapeutic directions are named in relation to this.<ref name=":0">{{Cite journal| doi = 10.1159/000346849| issn = 1661-4127| volume = 20| issue = 1| pages = 43–57| last = Matthiessen| first = Peter F.| title = Komplementärmedizin und Wissenschaftspluralismus - von der staatlichen Forschungsförderung zum Dialogforum Pluralismus in der Medizin| journal = Forschende Komplementärmedizin / Research in Complementary Medicine| access-date = 2015-05-18| date = 2013| url = http://www.karger.com/doi/10.1159/000346849|via=|language=de}}</ref><ref name=":1">{{Cite journal| issue = 7/5091| pages = 7| last = Bundestagsausschuss für Jugend, Familie und Gesundheit| title = Präambel in Vorbereitung des 2. AMG vom 24. August 1976| journal = Bundestagsdrucksache| access-date = 2024-04-28| date = 1976-04-28| url = https://dserver.bundestag.de/btd/07/050/0705091.pdf|first=|volume=|via=|language=de}}</ref>

'''Scientific pluralism''' refers to pluralism in science. This can take the form of [[pluralism of theories]], [[Methodological pluralism|methods]], paradigms or [[Plurality of perspectives|perspectives]]. In terms of [[medical pluralism]], scientific pluralism is assumed in the German Medicinal Products Act and three particular therapeutic directions are named in relation to this.<ref name=":0">{{Cite journal| doi = 10.1159/000346849| issn = 1661-4127| volume = 20| issue = 1| pages = 43–57| last = Matthiessen| first = Peter F.| title = Komplementärmedizin und Wissenschaftspluralismus - von der staatlichen Forschungsförderung zum Dialogforum Pluralismus in der Medizin| journal = Forschende Komplementärmedizin / Research in Complementary Medicine| access-date = 2015-05-18| date = 2013| url = http://www.karger.com/doi/10.1159/000346849|via=|language=de}}</ref><ref name=":1">{{Cite journal| issue = 7/5091| pages = 7| last = Bundestagsausschuss für Jugend, Familie und Gesundheit| title = Präambel in Vorbereitung des 2. AMG vom 24. August 1976| journal = Bundestagsdrucksache| access-date = 2024-04-28| date = 1976-04-28| url = https://dserver.bundestag.de/btd/07/050/0705091.pdf|first=|volume=|via=|language=de}}</ref>

== Scientific pluralism in the German Medicinal Products Act of 1976 ==

==Scientific pluralism in the German Medicinal Products Act of 1976==

The German Medicinal Products Act recognizes scientific pluralism, particularly with regard to the three special therapeutic directions. The report of the Committee for Youth, Family and Health (13th Committee)<ref name=":1" /> of 1976 states:<blockquote>In the reorganization of pharmaceutical law, the Committee proceeded from the fact that in the field of drug therapy, several therapeutic directions exist side by side, based on different theoretical approaches and scientific methods ... In the unanimous opinion of the Committee, it cannot and must not be the task of the legislator to elevate one of the competing therapeutic approaches to the status of a generally binding "state of scientific knowledge" and thus to the exclusive standard for the authorization of a medicinal product by unilaterally determining certain methods for proving the efficacy of a medicinal product. Rather, the Committee was guided by the political objective of clearly reflecting the scientific pluralism existing in drug therapy in the area of marketing authorization, particularly in the design of the requirements for proof of efficacy.<ref name=":0" /><ref>Translated from {{Cite journal| issue = 7/5091| pages = 7| last = Bundestagsausschuss für Jugend, Familie und Gesundheit| title = Präambel in Vorbereitung des 2. AMG vom 24. August 1976| journal = Bundestagsdrucksache| access-date = 2024-04-28| date = 1976-04-28| url = https://dserver.bundestag.de/btd/07/050/0705091.pdf|first=|volume=|via=|language=de}}</ref></blockquote>

The German Medicinal Products Act recognizes scientific pluralism, particularly with regard to the three special therapeutic directions. The report of the Committee for Youth, Family and Health (13th Committee)<ref name=":1" /> of 1976 states:<blockquote>In the reorganization of pharmaceutical law, the Committee proceeded from the fact that in the field of drug therapy, several therapeutic directions exist side by side, based on different theoretical approaches and scientific methods ... In the unanimous opinion of the Committee, it cannot and must not be the task of the legislator to elevate one of the competing therapeutic approaches to the status of a generally binding "state of scientific knowledge" and thus to the exclusive standard for the authorization of a medicinal product by unilaterally determining certain methods for proving the efficacy of a medicinal product. Rather, the Committee was guided by the political objective of clearly reflecting the scientific pluralism existing in drug therapy in the area of marketing authorization, particularly in the design of the requirements for proof of efficacy.<ref name=":0" /><ref>Translated from {{Cite journal| issue = 7/5091| pages = 7| last = Bundestagsausschuss für Jugend, Familie und Gesundheit| title = Präambel in Vorbereitung des 2. AMG vom 24. August 1976| journal = Bundestagsdrucksache| access-date = 2024-04-28| date = 1976-04-28| url = https://dserver.bundestag.de/btd/07/050/0705091.pdf|first=|volume=|via=|language=de}}</ref></blockquote>